COVID-19 vaccine generated a strong immune response and was generally well-tolerated in children aged six to 11 years, and the company plans to submit the data to regulators soon.Moderna said its two-dose vaccine generated virus-neutralizing antibodies in children and safety was comparable to what was previously seen in clinical trials of adolescents and adults.A panel of FDA advisers will vote on Tuesday whether to authorize rival Pfizer and BioNTech’s COVID-19 vaccine for use in children aged five to 11 years.The Moderna COVID-19 vaccine has been authorized for adults over the age of 18 years, and recently gained clearance for a third dose in some Americans.